8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Feb 26, 2026·SEC
Material company update
Jan 12, 2026·SEC
Syndax Pharmaceuticals, Inc.(SNDX)Earnings, Financials & Key Ratios
SNDX•NASDAQ
$20.65
$1.82B mkt cap·Price updated May 6, 2026
AboutSyndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.Show more
- Revenue$172M+627.8%
- EBITDA-$273M+19.6%
- Net Income-$285M+10.5%
- EPS (Diluted)-3.29+11.8%
- Gross Margin95.96%-0.6%
- EBITDA Margin-158.44%+89.0%
- Operating Margin-158.45%+89.0%
- Net Margin-165.6%+87.7%
- ROE-161.82%-113.8%
- ROIC-54.19%+21.3%
- Debt/Equity5.36+346.8%
- Interest Coverage-7.45+88.3%
SNDX Key Insights
Syndax Pharmaceuticals, Inc. (SNDX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 157.7%
✗Weaknesses
- ✗High debt to equity ratio of 5.4x
- ✗Profits declining 31.3% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Expensive at 27.7x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
SNDX Price & Volume
Syndax Pharmaceuticals, Inc. (SNDX) stock price & volume — 10-year historical chart
Loading chart...
SNDX Growth Metrics
Syndax Pharmaceuticals, Inc. (SNDX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years75.35%
5 Years157.68%
3 Years-
TTM396.72%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM26.56%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM40.31%
Return on Capital
10 Years-51.19%
5 Years-36.43%
3 Years-51.9%
Last Year-52.98%
SNDX Recent Earnings
Syndax Pharmaceuticals, Inc. (SNDX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 2/12 qtrs (29%)
Q2 2026Latest
Apr 30, 2026EPS
$0.48
Est $0.59
+18.6%
Revenue
$65M
Est $70M
-7.0%
Q1 2026
Feb 26, 2026EPS
$0.78
Est $0.58
-33.6%
Revenue
$69M
Est $64M
+6.9%
Q4 2025
Nov 3, 2025EPS
$0.70
Est $0.74
+5.4%
Revenue
$46M
Est $63M
-27.6%
Q3 2025
Aug 4, 2025EPS
$0.83
Est $1.00
+17.0%
Revenue
$38M
Est $46M
-16.9%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $0.48vs $0.59+18.6% | $65Mvs $70M-7.0% |
| Q1 2026 | Feb 26, 2026 | $0.78vs $0.58-33.6% | $69Mvs $64M+6.9% |
| Q4 2025 | Nov 3, 2025 | $0.70vs $0.74+5.4% | $46Mvs $63M-27.6% |
| Q3 2025 | Aug 4, 2025 | $0.83vs $1.00+17.0% | $38Mvs $46M-16.9% |
Based on last 12 quarters of dataView full earnings history →
SNDX Peer Comparison
Syndax Pharmaceuticals, Inc. (SNDX) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 RVMD | 32.12B | 151.07 | -25.39 | -83.22% | 0.10 | |||
 TGTX | 6.7B | 41.97 | 15.15 | 87.32% | 65.95% | 87.36% | 0.40 | |
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 VERA | 2.62B | 36.60 | -7.85 | -59.72% | 0.13 | |||
 IOVA | 1.68B | 4.09 | -3.75 | 60.6% | -148.38% | -55.97% | 0.07 | |
 FATE | 264.17M | 2.29 | -1.99 | -51.24% | -20.51% | -65.79% | 0.38 |
Compare SNDX vs Peers
Syndax Pharmaceuticals, Inc. (SNDX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SNDX Income Statement
Syndax Pharmaceuticals, Inc. (SNDX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 2.11M | 1.52M | 1.52M | 1.52M | 139.71M | 0 | 0 | 23.68M | 172.35M | 217.17M |
| Revenue Growth % | 72.79% | -28.04% | 0% | 0% | 9109.56% | -100% | - | - | 627.84% | 396.72% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 826K | 6.97M | 4.44M |
| COGS % of Revenue | - | - | - | - | - | - | - | 3.49% | 4.04% | - |
| Gross Profit | 2.11M▲ 0% | 1.52M▼ 28.0% | 1.52M▲ 0.0% | 1.52M▲ 0.0% | 139.71M▲ 9109.6% | 0▼ 100.0% | 0▲ 0% | 22.85M▲ 0% | 165.38M▲ 623.6% | 212.73M▲ 0% |
| Gross Margin % | 100% | 100% | 100% | 100% | 100% | - | - | 96.51% | 95.96% | 97.96% |
| Gross Profit Growth % | 72.79% | -28.04% | 0% | 0% | 9109.56% | -100% | - | - | 623.65% | - |
| Operating Expenses | 64.06M | 77.39M | 59.06M | 72.94M | 113.49M | 151.76M | 229.95M | 362.53M | 438.47M | 436.26M |
| OpEx % of Revenue | 3038.99% | 5101.71% | 3892.95% | 4808.17% | 81.23% | - | - | 1530.94% | 254.4% | - |
| Selling, General & Admin | 15.86M | 17.29M | 16.06M | 22.5M | 25.24M | 33.26M | 66.92M | 120.88M | 179.68M | 176.24M |
| SG&A % of Revenue | 752.42% | 1139.55% | 1058.8% | 1483.52% | 18.07% | - | - | 510.47% | 104.25% | - |
| Research & Development | 48.2M | 60.11M | 42.99M | 50.44M | 88.25M | 118.5M | 163.03M | 241.65M | 258.78M | 255.99M |
| R&D % of Revenue | 2286.57% | 3962.16% | 2834.15% | 3324.65% | 63.17% | - | - | 1020.47% | 150.15% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1000K |
| Operating Income | -61.95M▲ 0% | -75.88M▼ 22.5% | -57.54M▲ 24.2% | -71.42M▼ 24.1% | 26.22M▲ 136.7% | -151.76M▼ 678.8% | -229.95M▼ 51.5% | -339.67M▼ 47.7% | -273.08M▲ 19.6% | -223.53M▲ 0% |
| Operating Margin % | -2938.99% | -5001.71% | -3792.95% | -4708.17% | 18.77% | - | - | -1434.43% | -158.45% | -102.93% |
| Operating Income Growth % | -41.56% | -22.47% | 24.17% | -24.13% | 136.71% | -678.78% | -51.53% | -47.71% | 19.6% | - |
| EBITDA | -61.88M | -75.8M | -57.09M | -70.91M | 26.26M | -151.72M | -229.94M | -339.66M | -273.08M | -218.16M |
| EBITDA Margin % | -2935.39% | -4996.57% | -3763.22% | -4674.23% | 18.8% | - | - | -1434.39% | -158.44% | -100.45% |
| EBITDA Growth % | -41.67% | -22.5% | 24.68% | -24.21% | 137.04% | -677.71% | -51.55% | -47.72% | 19.6% | 33.44% |
| D&A (Non-Cash Add-back) | 76K | 78K | 451K | 515K | 43K | 33K | 12K | 8K | 6K | 6K |
| EBIT | -61.95M | -73.96M | -56.05M | -70.8M | 26.82M | -146.2M | -209.15M | -313.83M | -251.64M | -131.73M |
| Net Interest Income | 1.42M | 1.94M | 1.57M | -1.52M | -1.5M | 2.73M | 20.95M | 21.16M | -11.05M | -48.03M |
| Interest Income | 0 | 0 | 1.57M | 841K | 403K | 5.87M | 21.16M | 26.09M | 22.73M | 24.38M |
| Interest Expense | 1.42M | 1.94M | 0 | 2.36M | 1.9M | 3.14M | 208K | 4.93M | 33.78M | 57M |
| Other Income/Expense | 1.15M | 1.92M | 1.49M | -1.74M | -1.29M | 2.42M | 20.59M | 20.91M | -12.34M | -19.72M |
| Pretax Income | -60.8M▲ 0% | -73.96M▼ 21.6% | -56.05M▲ 24.2% | -73.16M▼ 30.5% | 24.93M▲ 134.1% | -149.34M▼ 699.1% | -209.36M▼ 40.2% | -318.76M▼ 52.3% | -285.42M▲ 10.5% | -243.25M▲ 0% |
| Pretax Margin % | -2884.35% | -4875.48% | -3694.59% | -4822.54% | 17.84% | - | - | -1346.11% | -165.6% | -112.01% |
| Income Tax | -76K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0.12% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -60.8M▲ 0% | -73.96M▼ 21.6% | -55.95M▲ 24.3% | -73.07M▼ 30.6% | 24.93M▲ 134.1% | -149.34M▼ 699.1% | -209.36M▼ 40.2% | -318.76M▼ 52.3% | -285.42M▲ 10.5% | -243.25M▲ 0% |
| Net Margin % | -2884.35% | -4875.48% | -3688.53% | -4816.68% | 17.84% | - | - | -1346.11% | -165.6% | -112.01% |
| Net Income Growth % | -36.72% | -21.64% | 24.35% | -30.59% | 134.11% | -699.13% | -40.19% | -52.25% | 10.46% | 26.56% |
| Net Income (Continuing) | -60.8M | -73.96M | -56.05M | -73.16M | 24.93M | -149.34M | -209.36M | -318.76M | -285.42M | -243.25M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.90▲ 0% | -2.92▼ 0.7% | -1.84▲ 37.0% | -1.77▲ 3.8% | 0.48▲ 127.1% | -2.46▼ 612.5% | -2.98▼ 21.1% | -3.73▼ 25.2% | -3.29▲ 11.8% | -▲ 0% |
| EPS Growth % | 4.61% | -0.69% | 36.99% | 3.8% | 127.12% | -612.5% | -21.14% | -25.17% | 11.8% | 40.31% |
| EPS (Basic) | -2.90 | -2.92 | -1.84 | -1.77 | 0.48 | -2.46 | -2.98 | -3.73 | -3.29 | - |
| Diluted Shares Outstanding | 21M | 25.37M | 30.49M | 41.31M | 52.06M | 60.76M | 70.37M | 85.62M | 86.63M | 0 |
| Basic Shares Outstanding | 21M | 25.37M | 30.49M | 41.31M | 52.06M | 60.76M | 70.37M | 85.62M | 86.63M | 0 |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
SNDX Balance Sheet
Syndax Pharmaceuticals, Inc. (SNDX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 133.44M | 83.35M | 62.33M | 298.86M | 448.4M | 489.79M | 580.88M | 603.06M | 528.08M | 471.18M |
| Cash & Short-Term Investments | 133.22M | 80.91M | 59.77M | 293.06M | 446.83M | 484.4M | 577.58M | 582.91M | 394.07M | 352.06M |
| Cash Only | 35.17M | 33.77M | 24.61M | 115.24M | 221.97M | 74.36M | 295.39M | 154.08M | 134.93M | 130.89M |
| Short-Term Investments | 94.81M | 47.14M | 35.17M | 177.82M | 224.87M | 410.04M | 282.19M | 428.83M | 259.14M | 221.17M |
| Accounts Receivable | 377K | 253K | 116K | 175K | 429K | 4.06M | 1.23M | 13.87M | 38M | 38.12M |
| Days Sales Outstanding | 65.28 | 60.87 | 27.91 | 42.11 | 1.12 | - | - | 213.81 | 80.47 | 58.38 |
| Inventory | -1.44M | 1.05M | 0 | 0 | 0 | 0 | 0 | 366K | 32.75M | 34.95M |
| Days Inventory Outstanding | - | - | - | - | - | - | - | 161.73 | 1.72K | 2.32K |
| Other Current Assets | 1.29M | 1.79M | 2.06M | 456K | 265K | 117K | 63K | -2.02M | 63.26M | 46.05M |
| Total Non-Current Assets | 3.74M | 592K | 1.19M | 1.75M | 1.26M | 7.45M | 32M | 121.76M | 1.63M | 1.49M |
| Property, Plant & Equipment | 267K | 373K | 997K | 482K | 1.26M | 1.06M | 1.5M | 2.02M | 1.52M | 1.39M |
| Fixed Asset Turnover | 7.90x | 4.07x | 1.52x | 3.15x | 110.79x | - | - | 11.71x | 113.17x | 141.48x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 3.25M | 0 | 115K | 0 | 0 | 5.47M | 29.83M | 119.52M | 0 | 82.88M |
| Other Non-Current Assets | 231K | 219K | 82K | 1.27M | 0 | 922K | 680K | 217K | 102K | 536K |
| Total Assets | 137.19M▲ 0% | 83.94M▼ 38.8% | 63.52M▼ 24.3% | 300.61M▲ 373.2% | 449.66M▲ 49.6% | 497.24M▲ 10.6% | 612.88M▲ 23.3% | 724.82M▲ 18.3% | 529.71M▼ 26.9% | 472.67M▲ 0% |
| Asset Turnover | 0.02x | 0.02x | 0.02x | 0.01x | 0.31x | - | - | 0.03x | 0.33x | 0.40x |
| Asset Growth % | 25.84% | -38.81% | -24.32% | 373.22% | 49.58% | 10.58% | 23.26% | 18.26% | -26.92% | 1.43% |
| Total Current Liabilities | 15.8M | 16.11M | 18.37M | 18.87M | 20.68M | 29.07M | 58.1M | 103.55M | 120.12M | 86.17M |
| Accounts Payable | 2.23M | 1.44M | 6.18M | 3.51M | 5.67M | 4.35M | 9.96M | 11.63M | 16.58M | 10.84M |
| Days Payables Outstanding | - | - | - | - | - | - | - | 5.14K | 868.25 | 1.2K |
| Short-Term Debt | 0 | 0 | 0 | 2.29M | 0 | 0 | 0 | 12.12M | 472K | 0 |
| Deferred Revenue (Current) | 1.57M | 1.52M | 1.52M | 1.52M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 9.6M | 10.35M | 7.39M | 3.74M | 6.23M | 6.55M | 35.92M | 79.33M | 103.06M | 75.33M |
| Current Ratio | 8.45x | 5.18x | 3.39x | 15.84x | 21.68x | 16.85x | 10.00x | 5.82x | 4.40x | 4.40x |
| Quick Ratio | 8.54x | 5.11x | 3.39x | 15.84x | 21.68x | 16.85x | 10.00x | 5.82x | 4.12x | 4.12x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | -4.76K | 927.45 | 1.17K |
| Total Non-Current Liabilities | 17.07M | 14.79M | 13.56M | 29.55M | 20.61M | 722K | 588K | 333.14M | 344.96M | 258.7M |
| Long-Term Debt | 0 | 0 | 0 | 17.83M | 19.89M | 0 | 0 | 331.56M | 344.96M | 0 |
| Capital Lease Obligations | 0 | 0 | 419K | 101K | 711K | 722K | 588K | 1.58M | 1.05M | 3.57M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 310K | 136K | 5K | 1K | 0 | 0 | 0 | 0 | -1.05M | 582.06M |
| Total Liabilities | 32.87M | 30.89M | 31.93M | 48.42M | 41.29M | 29.79M | 58.68M | 436.69M | 465.08M | 344.87M |
| Total Debt | 0 | 0 | 897K | 20.54M | 20.97M | 1.16M | 1.64M | 345.74M | 346.48M | 0 |
| Net Debt | -35.17M | -33.77M | -23.71M | -94.71M | -201M | -73.19M | -293.76M | 191.66M | 211.55M | -130.89M |
| Debt / Equity | - | - | 0.03x | 0.08x | 0.05x | 0.00x | 0.00x | 1.20x | 5.36x | 5.36x |
| Debt / EBITDA | - | - | - | - | 0.80x | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | -7.65x | - | - | - | - | 0.60x |
| Interest Coverage | -43.60x | -38.08x | - | -30.04x | 14.13x | -46.61x | -1005.54x | -63.67x | -7.45x | -2.31x |
| Total Equity | 104.32M▲ 0% | 53.05M▼ 49.1% | 31.6M▼ 40.4% | 252.19M▲ 698.1% | 408.37M▲ 61.9% | 467.45M▲ 14.5% | 554.2M▲ 18.6% | 288.12M▼ 48.0% | 64.63M▼ 77.6% | 41.62M▲ 0% |
| Equity Growth % | 23.98% | -49.15% | -40.43% | 698.06% | 61.93% | 14.47% | 18.56% | -48.01% | -77.57% | -290.47% |
| Book Value per Share | 4.97 | 2.09 | 1.04 | 6.11 | 7.84 | 7.69 | 7.88 | 3.37 | 0.75 | 0.47 |
| Total Shareholders' Equity | 104.32M | 53.05M | 31.6M | 252.19M | 408.37M | 467.45M | 554.2M | 288.12M | 64.63M | 41.62M |
| Common Stock | 2K | 2K | 3K | 5K | 6K | 7K | 8K | 9K | 9K | 9K |
| Retained Earnings | -366.11M | -439.42M | -495.47M | -568.63M | -543.7M | -693.04M | -902.4M | -1.22B | -1.51B | -1.55B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -143K | -25K | 0 | -4K | 45K | -806K | 218K | 163K | 452K | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SNDX Cash Flow Statement
Syndax Pharmaceuticals, Inc. (SNDX) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -47.37M | -68.53M | -50.61M | -71.26M | 29.13M | -133.68M | -160.6M | -274.9M | -322.98M | -322.98M |
| Operating CF Margin % | -2247.2% | -4517.53% | -3336.32% | -4697.43% | 20.85% | - | - | -1160.91% | -187.4% | - |
| Operating CF Growth % | -34.74% | -44.67% | 26.15% | -40.8% | 140.88% | -558.88% | -20.14% | -71.17% | -17.49% | -9.71% |
| Net Income | -60.8M | -73.96M | -56.05M | -73.16M | 24.93M | -149.34M | -209.36M | -318.76M | -285.42M | -243.25M |
| Depreciation & Amortization | 76K | 78K | 92K | 89K | 43K | 33K | 12K | 8K | 6K | -102K |
| Stock-Based Compensation | 5.45M | 6.2M | 6M | 9.06M | 13.32M | 16.02M | 30.95M | 43.03M | 47.5M | 49.18M |
| Deferred Taxes | 223K | -558K | -780K | 0 | 255K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 8K | 11K | 359K | 686K | 187K | -2.04M | -14.06M | -12.45M | -5.75M | -22.1M |
| Working Capital Changes | 7.67M | -302K | -241K | -7.93M | -9.6M | 1.66M | 31.86M | 13.27M | -79.32M | -61.89M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | -3.47M | 0 | -11.24M | -36.83M | -28.88M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 3.47M | 0 | -366K | -32.09M | -29.96M |
| Change in Payables | -194K | -792K | 4.74M | -2.67M | 2.16M | -1.32M | 5.61M | 1.67M | 4.95M | 796K |
| Cash from Investing | -17.03M | 51.4M | 12.78M | -142.53M | -40.87M | -186.19M | 117.61M | -219.78M | 290.04M | 234.28M |
| Capital Expenditures | -84K | -187K | 0 | 0 | -129K | -225K | 0 | 0 | -187K | -187K |
| CapEx % of Revenue | 3.98% | 12.33% | - | - | 0.09% | - | - | - | 0.11% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 40.74K | 225K | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 45K | 51.59K | 12.78K | 0 | -40.74K | 225K | 0 | 0 | 0 | 0 |
| Cash from Financing | 75.72M | 15.73M | 28.57M | 304.42M | 118.46M | 172.25M | 264.13M | 353.37M | 13.68M | 20.66M |
| Debt Issued (Net) | 0 | 0 | 0 | 19.73M | 0 | -21M | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 75.35M | 15.5M | 28.21M | 278.06M | 86.34M | 181.39M | 258.09M | 9.71M | 13.68M | 12.75M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 374K | 232K | 360K | 6.63M | 32.13M | 11.86M | 6.04M | 343.65M | 0 | 7.92M |
| Net Change in Cash | 11.32M▲ 0% | -1.4M▼ 112.4% | -9.26M▼ 559.6% | 90.63M▲ 1078.7% | 106.72M▲ 17.8% | -147.61M▼ 238.3% | 221.14M▲ 249.8% | -141.31M▼ 163.9% | -19.27M▲ 86.4% | -23.21M▲ 0% |
| Free Cash Flow | -47.45M▲ 0% | -68.72M▼ 44.8% | -50.61M▲ 26.3% | -71.26M▼ 40.8% | 29M▲ 140.7% | -133.9M▼ 561.7% | -160.6M▼ 19.9% | -274.9M▼ 71.2% | -323.17M▼ 17.6% | -278.35M▲ 0% |
| FCF Margin % | -2251.19% | -4529.86% | -3336.32% | -4697.43% | 20.76% | - | - | -1160.91% | -187.5% | -128.17% |
| FCF Growth % | -33.99% | -44.81% | 26.35% | -40.8% | 140.7% | -561.69% | -19.94% | -71.17% | -17.56% | 2.85% |
| FCF per Share | -2.26 | -2.71 | -1.66 | -1.73 | 0.56 | -2.20 | -2.28 | -3.21 | -3.73 | -3.73 |
| FCF Conversion (FCF/Net Income) | 0.78x | 0.93x | 0.90x | 0.98x | 1.17x | 0.90x | 0.77x | 0.86x | 1.13x | 1.14x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SNDX Key Ratios
Syndax Pharmaceuticals, Inc. (SNDX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -64.53% | -94% | -132.21% | -51.5% | 7.55% | -34.1% | -40.98% | -75.69% | -161.82% | -256.66% |
| Return on Invested Capital (ROIC) | -71.79% | -128.71% | -317.71% | -64.79% | 10.78% | -37.84% | -52.69% | -68.83% | -54.19% | -54.19% |
| Gross Margin | 100% | 100% | 100% | 100% | 100% | - | - | 96.51% | 95.96% | 97.96% |
| Net Margin | -2884.35% | -4875.48% | -3688.53% | -4816.68% | 17.84% | - | - | -1346.11% | -165.6% | -112.01% |
| Debt / Equity | - | - | 0.03x | 0.08x | 0.05x | 0.00x | 0.00x | 1.20x | 5.36x | 5.36x |
| Interest Coverage | -43.60x | -38.08x | - | -30.04x | 14.13x | -46.61x | -1005.54x | -63.67x | -7.45x | -2.31x |
| FCF Conversion | 0.78x | 0.93x | 0.90x | 0.98x | 1.17x | 0.90x | 0.77x | 0.86x | 1.13x | 1.14x |
| Revenue Growth | 72.79% | -28.04% | 0% | 0% | 9109.56% | -100% | - | - | 627.84% | 396.72% |
SNDX SEC Filings & Documents
Syndax Pharmaceuticals, Inc. (SNDX) SEC filings — annual & quarterly reports (10-K, 10-Q)
SNDX Frequently Asked Questions
Syndax Pharmaceuticals, Inc. (SNDX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Syndax Pharmaceuticals, Inc. (SNDX) reported $217.2M in revenue for fiscal year 2025.
Syndax Pharmaceuticals, Inc. (SNDX) grew revenue by 627.8% over the past year. This is strong growth.
Syndax Pharmaceuticals, Inc. (SNDX) reported a net loss of $243.2M for fiscal year 2025.
Dividend & Returns
Syndax Pharmaceuticals, Inc. (SNDX) has a return on equity (ROE) of -161.8%. Negative ROE indicates the company is unprofitable.
Syndax Pharmaceuticals, Inc. (SNDX) had negative free cash flow of $278.4M in fiscal year 2025, likely due to heavy capital investments.
Explore More SNDX
Syndax Pharmaceuticals, Inc. (SNDX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates